Edwards Lifesciences Services GmbH - Device Unbefristete Anstellungen

[12.12.2024] --Transcatheter Mitral & Tricuspid Therapies (TMTTs) are the future of Edwards – Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aimed at transforming care for the many patients suffering from mitral and...